Phase I/II Clinical Study of Forodesine in Japanese Recurrent/Refractory Peripheral T-cell Lymphoma Patients
This trial is active, not recruiting.
|Condition||recurrent or refractory ptcl|
|Phase||phase 1/phase 2|
|Start date||January 2013|
|End date||December 2015|
|Trial size||49 participants|
|Trial identifier||NCT01776411, FDS-J02|
Phase I portion:
To confirm safety and tolerability in recurrent/refractory peripheral T-cell lymphoma patients during repeated oral administration of forodesine 300 mg twice daily (600 mg/day) for 28 days, and determine the recommended dose. Also, to evaluate pharmacokinetics.
Phase II portion:
To evaluate the efficacy, safety, and pharmacokinetics of the recommended dosage regimen determined in the phase I portion. The primary efficacy endpoint shall be objective response rate (ORR).
|United States||No locations recruiting|
|Other countries||No locations recruiting|
|Nagoya, Japan||Nagoya Daini Red Cross Hospital||no longer recruiting|
|Nagoya, Japan||National Hospital Organization Nagoya Medical Center||no longer recruiting|
|Kashiwa, Japan||National Cancer Center Hospital East||no longer recruiting|
|Matsuyama, Japan||National Hospital Organization Shikoku Cancer Center||no longer recruiting|
|Maebashi, Japan||Gunma University Hospital||no longer recruiting|
|Sapporo, Japan||National Hospital Organization Hokkaido Cancer Center||no longer recruiting|
|Akashi, Japan||Hyogo Cancer Center||no longer recruiting|
|Isehara, Japan||Tokai University Hospital||no longer recruiting|
|Sendai, Japan||Tohoku University Hospital||no longer recruiting|
|Suita, Japan||Osaka University Hospital||no longer recruiting|
|Izumo, Japan||Shimane University Hospital||no longer recruiting|
|Utsunomiya, Japan||Tochigi Cancer Center||no longer recruiting|
|Chuo, Japan||National Cancer Center Hospital||no longer recruiting|
|Koto, Japan||The Cancer Institute Hospital Japanese Foundation for Cancer Research||no longer recruiting|
|Fukui, Japan||University of Fukui Hospital||no longer recruiting|
|Fukuoka, Japan||Fukuoka University Hospital||no longer recruiting|
|Fukuoka, Japan||National Hospital Organization Kyushu Cancer Center||no longer recruiting|
|Kagoshima, Japan||Imamura Bun-in Hospital||no longer recruiting|
|Kumamoto, Japan||National Hospital Organization Kumamoto Medical Center||no longer recruiting|
|Kyoto, Japan||University Hospital, Kyoto Prefectural University of Medicine||no longer recruiting|
|Okayama,, Japan||Okayama University Hospital||no longer recruiting|
|Endpoint classification||safety/efficacy study|
|Intervention model||single group assignment|
Drug: forodesine hydrochloride 600 mg / body/day (3 x 100 mg capsules twice daily)
Objective response rate (ORR) based on evaluation by image assessment committee
time frame: 2 years
Male or female participants at least 20 years old.
- Japanese patients at least 20 years of age.
- Patients histologically diagnosed with peripheral T-cell lymphoma by pathological diagnosis of biopsied lesion. In this study, peripheral T-cell lymphoma is defined as the following mature T-cell/NK-cell neoplasms found in the 4th edition of the WHO Classification.
- Recurrent/refractory patients with a treatment history of at least one regimen.
- Patients with an enlarged lymph node or extranodal mass lesion clearly measurable in two perpendicular directions and greater than 1.5 cm in maximum diameter on computed tomography performed.
- Patients expected to survive for at least 3 months.
- ECOG PS 0-1.
- Patients with adequate hemopoietic efficacy, liver and kidney function.
- Patients from whom written consent has been obtained prior to study initiation.
- Patients who received a chemotherapy agent or a high dose of a systemic adrenocorticosteroid within 21 days prior to initial administration of the study drug.
- Patients who received radiation therapy, phototherapy, or electron beam therapy within 21 days prior to initial administration of the study drug.
- Patients who received another study drug within 28 days prior to initial administration of the study drug.
- Patients who received antibody therapy within 100 days prior to initial administration of the study drug.
- Patients with a history of allogeneic hematopoietic stem cell transplantation. Or patients with a history of autologous hematopoietic stem cell transplantation within 100 days prior to initial administration of the study drug.
- Patients with cerebral metastasis or central nervous system lesion or a past history.
- Patients with active multiple primary cancer. Or patients with a history of a malignant neoplasm other than peripheral T-cell lymphoma within the past 5 years.
- Patients with severe cardiovascular disease.
- Patients with congenital long QT syndrome.
- Patients with QTcF >0.48 sec.
- Patients positive for HBs antigen, HCV antibody or HIV antibody on immunological investigation. Or patients positive for either HBc antibody or HBs antibody, and showing DNA more than sensitivity in HBV-DNA assay.
- Patients positive for CMV antigen on immunological investigation.
- Patients with infectious disease requiring treatment consisting of intravenous administration of antibacterial agent, fungicide, or antiviral drug.
- Patients with interstitial pneumonia or pulmonary fibrosis, or patients judged to have insufficient pulmonary function.
|Official title||Phase I/II Clinical Study of Forodesine in Japanese Recurrent/Refractory Peripheral T-cell Lymphoma Patients|
|Principal investigator||Kensei Tobinai, MD,PhD|
Call for more information